<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04274114</url>
  </required_header>
  <id_info>
    <org_study_id>PS18-00018</org_study_id>
    <nct_id>NCT04274114</nct_id>
  </id_info>
  <brief_title>Treatment of Adults With Generalized Anxiety Disorder Using Glutamine</brief_title>
  <official_title>Efficacy of L-glutamine for the Treatment of Generalized Anxiety Disorder: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitario Dr. Jose E. Gonzalez</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto de Información e Investigación en Salud Mental A. C.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Universitario Dr. Jose E. Gonzalez</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this randomized clinical trial is to examine the efficacy of L-glutamine for
      the treatment of generalized anxiety disorder compared versus placebo.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 18, 2019</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response on Clinical Global Impression-Improvement</measure>
    <time_frame>Change from baseline to week 8</time_frame>
    <description>Score of 1 or 2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response on Hamilton Anxiety Rating Scale</measure>
    <time_frame>Change from baseline to week 8</time_frame>
    <description>Reduction of baseline score major or equal to 50 %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of Hamilton Anxiety Rating Scale score</measure>
    <time_frame>Change from baseline to week 8</time_frame>
    <description>Difference between baseline and final score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Generalized Anxiety Disorder</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this group will receive flexible doses of L-glutamine ranging from 5 to 25 grams once daily for 8 weeks. L-glutamine is administered as a powder dissolved in water.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients in this group will receive flexible doses of placebo ranging from 5 to 25 grams once daily for 8 weeks. Placebo is administered as a powder dissolved in water.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L Glutamine</intervention_name>
    <description>Powder</description>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Powder</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Outpatients with generalized anxiety disorder defined by the criteria of the
             Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V)

          -  Generalized anxiety disorder is the primary psychiatric disorder.

          -  Untreated patients or; patients treated with paroxetine, sertraline, citalopram,
             escitalopram, venlafaxine or duloxetine at least for 6 weeks on a stable dose; or
             patients treated with any benzodiazepine at least for 4 weeks on a stable dose.

          -  Hamilton Anxiety Rating Scale score major or equal to 20 and a score major or equal to
             2 on items 1 and 2 of the same scale at both screening and baseline.

          -  Clinical Global Impression-Severity major or equal to 4 at both screening and
             baseline.

        Exclusion Criteria:

          -  Unable to give informed consent.

          -  Currently participating in another clinical research.

          -  Any other psychiatric disorder not included in the Anxiety Disorders section of the
             Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V).
             Secondary diagnosis of other anxiety disorders are allowed provided the diagnosis is
             not more prominent than generalized anxiety disorder symptoms.

          -  Suicide risk as assessed by the researcher at screening or baseline.

          -  History of substance abuse in the previous six months before the screening visit.

          -  Suffering a medically relevant or instable disease.

          -  If woman, being pregnant at screening visit.

          -  If woman, being breastfeeding.

          -  A score major or equal to 20 on the Montgomery-Asberg Depression Rating Scale at
             screening or baseline.

          -  As judged by a researcher, the patient might not adhere to the intervention or
             complete follow-up.

          -  History of use of a banned drug in the past two weeks prior the baseline visit; three
             weeks in the case of monoamine oxidase inhibitors; one week in the case of fluvoxamine
             or a tricyclic antidepressant; two weeks for any antipsychotic and; six weeks por
             long-acting injectable antipsychotics.

          -  History of use of L-glutamine the most part of the days of the previous month before
             the baseline visit.

          -  History of psychotherapy treatment in the past month before the baseline visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>José A Ontiveros Sánchez De la Barquera, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Universitario Dr. Jose E. Gonzalez</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luis A Centeno Gándara, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Dr. Jose E. Gonzalez</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>José A Ontiveros Sánchez De la Barquera, MD, PhD</last_name>
    <phone>+52 1 81 8401 6525</phone>
    <email>ontiverosalf@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Luis A Centeno Gándara, MD</last_name>
    <phone>+ 52 1 33 1571 7716</phone>
    <email>luiscenteno@live.com.mx</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitario Dr. Jose E. Gonzalez</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo León</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José A Ontiveros Sánchez De la Barquera, MD, PhD</last_name>
      <phone>+51 1 81 8348 0585</phone>
      <email>ontiverosalf@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Luis A Centeno Gándara, MD</last_name>
      <phone>+51 1 81 8348 0585</phone>
      <email>luiscenteno@live.com.mx</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 14, 2020</study_first_submitted>
  <study_first_submitted_qc>February 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2020</study_first_posted>
  <last_update_submitted>February 17, 2020</last_update_submitted>
  <last_update_submitted_qc>February 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitario Dr. Jose E. Gonzalez</investigator_affiliation>
    <investigator_full_name>José Alfonso Ontiveros Sánchez De la Barquera</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>generalized anxiety disorder</keyword>
  <keyword>randomized controlled trial</keyword>
  <keyword>psychopharmacology</keyword>
  <keyword>drug therapy</keyword>
  <keyword>glutamine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

